ASXApplication for quotation of securities - LDX
other announcement
LDX
Health Care Equipment & Services
Lumos Diagnostics Holdings
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 15 Oct 2026
- Reported shorts
- 2.5K
- Shares on issue
- 971.666M
Lumos Diagnostics Holdings (LDX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Q1 FY27 Quarterly Results Date & Webinar Invitation
other announcement
Final Director's Interest Notice - LM
other announcement
Initial Director's Interest Notice - AS
other announcement
Notice of Annual General Meeting and Proxy Form
other announcement
Notification of cessation of securities - LDX
other announcement
Application for quotation of securities - LDX
other announcement
Change in substantial holding from RYD
other announcement
Application for quotation of securities - LDX
other announcement
FebriDx Commercial Traction Continues Across US Accounts
other announcement
Google NewsLumos Diagnostics (ASX:LDX): FebriDx Growth, US Reimbursement and Cash Use Take Centre Stage - Kalkine
Lumos Diagnostics (ASX:LDX): FebriDx Growth, US Reimbursement and Cash Use Take Centre Stage Kalkine
Application for quotation of securities - LDX
other announcement
Change of Director's Interest Notice - DW
director_dealing announcement
StockheadLumos Diagnostics lands PHASE Scientific order as US FebriDx rollout gathers pace
Product delivery will be fulfilled progressively between now and October 2026, with revenue recognised upon shipment. ... Read More The post Lumos Diagnostics lands PHASE Scientific order as US FebriDx rollout gathers pace appeared first on Stockhead.
Biocurious: Lumos seeks to net the ‘whales’ in US FebriDx rollout
Lumos is focussing on the biggest 'whale' customers as it seeks a US market foothold for its virus-versus-bacterial assay, Febridx ... Read More The post Biocurious: Lumos seeks to net the ‘whales’ in US FebriDx rollout appeared first on Stockhead.
Lumos Secures Distribution for FebriDx in Romania
other announcement
Foster Stockbroking bullish on Lumos as FebriDx US rollout gains momentum
Foster Stockbroking sees positive, early signs in LDX's US rollout of the FebriDx point-of-care test, which distinguishes between bacterial and ... Read More The post Foster Stockbroking bullish on Lumos as FebriDx US rollout gains momentum appeared first on Stockhead.
Change of Director's Interest Notice - DW
director_dealing announcement
Lumos Diagnostics (ASX:LDX) Delivers FY26 Revenue Growth as FebriDx Gains U.S. Traction - Kalkine
Lumos Diagnostics (ASX:LDX) Delivers FY26 Revenue Growth as FebriDx Gains U.S. Traction Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why Did Lumos Diagnostics Shares Jump 19.79%? Here's What Investors Are Watching About ASX:LDX - Kalkine
Why Did Lumos Diagnostics Shares Jump 19.79%? Here's What Investors Are Watching About ASX:LDX Kalkine
Small CapsFebriDx Commercial Traction Across Priority US Accounts
other announcement
Q4 FY26 Results Release Date and Webinar Invitation
other announcement
Closure of A$5M Loan Facility with Major Shareholders
other announcement
Change of Director's Interest Notice - SL
director_dealing announcement
Lumos Diagnostics (ASX:LDX): Diagnostics Stock Rebounds as Healthcare Small Caps Find Momentum - Kalkine
Lumos Diagnostics (ASX:LDX): Diagnostics Stock Rebounds as Healthcare Small Caps Find Momentum Kalkine
KalkineCould Lumos Diagnostics Be Approaching a Turning Point?
Highlights Analysts expect Lumos Diagnostics to move towards profitability in the near term. The company continues expanding its point-of-care diagnostic capabilities across healthcare markets. A debt-free balance sheet provides additional financial flexibility as growth initiatives progress. Lumos Diagnostics is gaining attention as analysts assess its path towards profitability, supported by healthcare sector demand and a debt-free balance sheet. Healthcare technology companies often attrac...
Analysts Are Optimistic We'll See A Profit From Lumos Diagnostics Holdings Limited (ASX:LDX) - simplywall.st
Analysts Are Optimistic We'll See A Profit From Lumos Diagnostics Holdings Limited (ASX:LDX) simplywall.st
Change of Director's Interest Notice - CR
director_dealing announcement
Investor Presentation - FebriDx US Commercial Update
other announcement
Change of Director's Interest Notice - DW
director_dealing announcement
Lumos gains traction in US FebriDx rollout with strong early reimbursement signals
Lumos provides positive update on early commercial rollout of FebriDx test across US urgent care networks. ... Read More The post Lumos gains traction in US FebriDx rollout with strong early reimbursement signals appeared first on Stockhead.
FebriDx U.S. Rollout and Reimbursement Update - Amended
other announcement
FebriDx Paediatric Study Enrolment Milestone Achieved
other announcement
Lumos receives US$0.5m CLIA waiver milestone payment
other announcement
Change of Director's Interest Notice - CR
director_dealing announcement
Change of Director's Interest Notice - SL
director_dealing announcement